M Cooper

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi request reprint Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
    Maja J A de Jonge
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Invest New Drugs 31:751-9. 2013
  2. ncbi request reprint Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
    M J A de Jonge
    Daniel den Hoed Cancer Center Erasmus Medical Center, Rotterdam, The Netherlands
    Invest New Drugs 22:329-33. 2004
  3. pmc Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours
    M J A de Jonge
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Br J Cancer 91:1459-65. 2004
  4. ncbi request reprint Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
    M J A de Jonge
    Dept of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 42:1351-6. 2006
  5. ncbi request reprint Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours
    M J A de Jonge
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 42:1768-74. 2006
  6. doi request reprint Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
    Maja J A de Jonge
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    Eur J Cancer 46:3016-21. 2010
  7. doi request reprint Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
    M J A de Jonge
    Dept of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 47:1328-35. 2011

Collaborators

Detail Information

Publications7

  1. doi request reprint Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
    Maja J A de Jonge
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Invest New Drugs 31:751-9. 2013
    ..Further evaluation of the combination will be pursued, exploring both paz-800/lap-1500 and paz-400/lap-1000...
  2. ncbi request reprint Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
    M J A de Jonge
    Daniel den Hoed Cancer Center Erasmus Medical Center, Rotterdam, The Netherlands
    Invest New Drugs 22:329-33. 2004
    ..To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy regimen...
  3. pmc Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours
    M J A de Jonge
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Br J Cancer 91:1459-65. 2004
    ..In this study, the DLTs of XR11576 were diarrhoea and fatigue. The recommended dose for phase II studies of XR11576 is 120 mg administered orally, on days 1-5 every 21 days. Alternative regimens are currently being explored...
  4. ncbi request reprint Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
    M J A de Jonge
    Dept of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 42:1351-6. 2006
    ..Clinical activity resulting in FDA approval for both BAY 43-9006 and SU11248 has been noted. However, optimal inhibition of several targets might not be feasible at a dose with acceptable toxicity...
  5. ncbi request reprint Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours
    M J A de Jonge
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 42:1768-74. 2006
    ....
  6. doi request reprint Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
    Maja J A de Jonge
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    Eur J Cancer 46:3016-21. 2010
    ..v.) LiPlaCis. and to assess plasma and urine pharmacokinetics and plasma biomarkers...
  7. doi request reprint Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
    M J A de Jonge
    Dept of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 47:1328-35. 2011
    ..We assessed the maximal tolerated dose (MTD), evaluated the pharmacokinetics and preliminary anti-tumour efficacy of oral SU-014813 administered continuously in combination with docetaxel to patients with advanced solid tumours...